card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Best Practices for Integrating Biomarkers across the Drug Development Continuum

Home / Insights / Best Practices for Integrating Biomarkers across the Drug Development Continuum

The use of biomarkers throughout all phases of drug development plays an increasingly important role in the drug approval process. Biomarkers used in early discovery enable companies to identify the most promising drug candidates in preparation for preclinical studies, which help to characterize the safety, efficacy and toxicity of the early drug candidates. The value of a well-designed biomarker strategy then extends to first-in-human studies where the drug's activity, mechanism of action, safety, and proof of concept are tested. Once a drug candidate enters Phase II studies, the use of biomarkers in drug development shifts to identifying subjects that may have better responses to the drug, safety, decisions on dosing, as well as prognostic purposes. A well-designed biomarker strategy is the cornerstone for utilizing precision medicine in a study and determining the right treatment for the right patient. Biomarkers that demonstrate usefulness in patient selection or patient responsiveness may be utilized in further phase III studies and ultimately may lead to diagnostic markers. 

Download this presentation to learn more about important concepts of biomarker usage throughout the drug development process and to read case studies that demonstrate the value of biomarkers.

Speakers:
Patrice Hugo, PhD, Chief Scientific Officer 
Patrick Hurban, PhD, Senior Director and Global Head, Translational Genomics 
Linda Robbie, PhD 
Radha Krishnan, MD, Chief Pathologist and Senior Medical Director